A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 Administered as Single Intravenous Doses to Healthy Male Subjects
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Rifabutin (Primary)
- Indications Nosocomial pneumonia
- Focus Adverse reactions; First in man
- Sponsors BioVersys
- 07 Feb 2022 Status changed from recruiting to completed.
- 09 Oct 2021 Planned End Date changed from 31 Mar 2021 to 1 Jun 2022.
- 09 Oct 2021 Planned primary completion date changed from 31 Mar 2021 to 1 Mar 2022.